Ten years of anti-vascular endothelial growth factor therapy
N Ferrara, AP Adamis - Nature reviews Drug discovery, 2016 - nature.com
The targeting of vascular endothelial growth factor A (VEGFA), a crucial regulator of both
normal and pathological angiogenesis, has revealed innovative therapeutic approaches in …
normal and pathological angiogenesis, has revealed innovative therapeutic approaches in …
[HTML][HTML] Ocular drug delivery to the retina: current innovations and future perspectives
HM Kim, SJ Woo - Pharmaceutics, 2021 - mdpi.com
Treatment options for retinal diseases, such as neovascular age-related macular
degeneration, diabetic retinopathy, and retinal vascular disorders, have markedly expanded …
degeneration, diabetic retinopathy, and retinal vascular disorders, have markedly expanded …
[HTML][HTML] Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment
CR Baumal, B Bodaghi, M Singer, DJ Tanzer… - Ophthalmology …, 2021 - Elsevier
Purpose Recent reports have described a spectrum of uncommon findings of intraocular
inflammation (IOI), retinal vasculitis and/or retinal vascular occlusion in patients with …
inflammation (IOI), retinal vasculitis and/or retinal vascular occlusion in patients with …
Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration
Background Age‐related macular degeneration (AMD) is the most common cause of
uncorrectable severe vision loss in people aged 55 years and older in the developed world …
uncorrectable severe vision loss in people aged 55 years and older in the developed world …
Ranibizumab for neovascular age-related macular degeneration
Background Ranibizumab—a recombinant, humanized, monoclonal antibody Fab that
neutralizes all active forms of vascular endothelial growth factor A—has been evaluated for …
neutralizes all active forms of vascular endothelial growth factor A—has been evaluated for …
[HTML][HTML] Diabetic retinopathy and VEGF
N Gupta, S Mansoor, A Sharma, A Sapkal… - The open …, 2013 - ncbi.nlm.nih.gov
Diabetic retinopathy remains the leading vascular-associated cause of blindness throughout
the world. Its treatment requires a multidisciplinary interventional approach at both systemic …
the world. Its treatment requires a multidisciplinary interventional approach at both systemic …
[PDF][PDF] Age-related macular degeneration (AMD): pathogenesis and therapy
JZ Nowak - Pharmacological reports, 2006 - Citeseer
Age-related macular degeneration (AMD) is a disease leading to severe visual loss and
legal blindness in the elderly population. Its pathogenesis, likely multifactorial, involving a …
legal blindness in the elderly population. Its pathogenesis, likely multifactorial, involving a …
Meta-analysis of endophthalmitis after intravitreal injection of anti–vascular endothelial growth factor agents: causative organisms and possible prevention strategies
CA Mccannel - Retina, 2011 - journals.lww.com
Purpose: To report the rates of endophthalmitis and the spectrum of causative organisms
after intravitreal injection of anti-vascular endothelial growth factor agents and possible …
after intravitreal injection of anti-vascular endothelial growth factor agents and possible …
An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration
AE Fung, GA Lalwani, PJ Rosenfeld, SR Dubovy… - American journal of …, 2007 - Elsevier
PURPOSE: To evaluate an optical coherence tomography (OCT)-guided, variable-dosing
regimen with intravitreal ranibizumab for the treatment of patients with neovascular age …
regimen with intravitreal ranibizumab for the treatment of patients with neovascular age …
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1
CD Regillo, DM Brown, P Abraham, H Yue… - American journal of …, 2008 - Elsevier
PURPOSE: To evaluate the efficacy and safety of ranibizumab administered monthly for
three months and then quarterly in patients with subfoveal choroidal neovascularization …
three months and then quarterly in patients with subfoveal choroidal neovascularization …